2023 年第 1 期 第 18 卷

钠-葡萄糖共转运蛋白2抑制剂对心肾保护作用的研究进展

Research progress on cardiorenal protection of sodium-glucose cotransporter 2 inhibitors

作者：何苗1蒋立虹2马丽晶3郑锖2

英文作者：He Miao1 Jiang Lihong2 Ma Lijing3 Zheng Qiang2

单位：1云南省第一人民医院昆明理工大学附属医院心血管内科，昆明650200；2云南省第一人民医院昆明理工大学附属医院心脏大血管外科，昆明650200；3云南省第一人民医院昆明理工大学附属医院内分泌代谢科，昆明650200

英文单位：1Department of Cardiovascular Medicine Affiliated Hospital of Kunming University of Science and Technology Yunnan First People′s Hospital Kunming 650200 China; 2Department of Cardiovascular Surgery Affiliated Hospital of Kunming University of Science and Technology Yunnan First People′s Hospital Kunming 650200 China; 3Department of Endocrine Metabolism Affiliated Hospital of Kunming University of Science and Technology Yunnan First People′s Hospital Kunming 650200 China

关键词：钠-葡萄糖共转运蛋白2抑制剂；糖尿病；心肾保护作用

英文关键词：Sodium-glucosecotransporter-2inhibitors;Diabetesmellitus;Cardiorenalprotection

• 摘要：

• 钠-葡萄糖共转运蛋白2（SGLT-2）抑制剂是一种新型降糖药物，具有高选择性和特异性，可减少近曲小管对葡萄糖的重吸收，增加尿葡萄糖排出，从而达到降低血糖的目的。在治疗过程中发现，SGLT-2抑制剂在控制血糖的同时，对心脏及肾脏也产生保护作用。SGLT-2抑制剂可以通过降低患者体质量、改善能量代谢及降低血压等机制对心肾产生一定的积极作用。本综述简要阐述了SGLT-2抑制剂在临床诊疗过程中的重要地位及在心脏、肾脏方面所发挥的保护作用。

• Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a kind of novel hypoglycemic drug with high selectivity and specificity to reduce the reabsorption of glucose by proximal convoluted tubule and to increase urinary glucose excretion, thus achieving the purpose of reducing blood glucose.In the course of treatment, SGLT-2 inhibitors also produced cardiorenal protection while controlling blood glucose. SGLT-2 inhibitors have certain positive effects on the heart and kidney through mechanisms such as reducing patients′ body weight, improving energy metabolism and lowering blood pressure. This paper briefly describes the importance of SGLT-2 in the clinical diagnosis and treatment process and the protective role of SGLT-2 inhibitors in the heart and kidney.